ArticleJournal of the American Heart Association2025
Characterizing Heart Failure Across the Spectrum of the Preserved Ejection Fraction: Does Heart Failure With Supranormal Ejection Fraction Exist? Data From the Swedish Heart Failure Registry.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Heart Failure with Supranormal Ejection Fraction: An Emerging High-Risk Phenotype Within the Preserved Ejection Fraction Spectrum-A Systematic Review.Journal of clinical medicine · 2026Review
- Experimental Models for Studying Cardiovascular Dysfunction in Metabolic Syndrome.Handbook of experimental pharmacology · 2026Review
- A U-shaped relationship between left ventricular ejection fraction and risk of worsening heart failure.European journal of heart failure · 2025Article
- Central Adiposity or Hypertension: Which Drives Heart Failure With a Preserved Ejection Fraction?Journal of the American College of Cardiology · 2025Review
- Fabry Disease Screening in Patients with Idiopathic HCM or LVH: Data from the Multicentric Nationwide F-CHECK Study.Biomedicines · 2025Article
- Heart Failure Syndromes: Different Definitions of Different Diseases-Do We Need Separate Guidelines? A Narrative Review.Journal of clinical medicine · 2025Review
- Supranormal Ejection Fraction in Heart Failure: Exploring the Heterogeneity of a Distinct Clinical Phenotype.Journal of the American Heart Association · 2025Article
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSparce data suggest higher mortality in heart failure (HF) with left ventricular ejection fraction (EF) >65% to 70%. We characterized EF distribution, characteristics, and outcomes in patients with HF and EF ≥50%. METHODS AND
resultsThere were 5576 patients enrolled in the Swedish HF registry between 2017 and 2021 and included in the study; 21% had EF ≥60%, 5% EF ≥65%, and 1.5% EF ≥70%. Patient characteristics independently associated with EF ≥60% were assessed by multivariable logistic regression and were identified as being a diagnosis of hypertrophic cardiomyopathy, worse New York Heart Association class, hypertension, and valvular disease, whereas use of medications and devices also recommended for HF with reduced EF, male sex, history of ischemic heart disease, peripheral artery disease, and chronic obstructive pulmonary disease were associated with an EF of 50% to 59%. Outcomes (all-cause, cardiovascular, and noncardiovascular death; all-cause and HF hospitalizations) were assessed by univariable and multivariable Cox regressions with EF modeled as a spline. The risk of all-cause and noncardiovascular mortality and first all-cause hospitalization was higher with EF values >55% in crude but not adjusted analyses.
conclusionsAmong patients with HF with preserved EF, 21% had EF ≥60%. A higher EF was characterized by more severe symptoms, hypertrophic cardiomyopathy, hypertension, female sex, and valvular disease. Crude higher but not adjusted risk of all-cause and noncardiovascular mortality and of all-cause hospitalization was observed with EF values >55%, suggesting that prognostically impactful conditions were more prevalent in the upper bound of the EF spectrum.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.